Martin A Heckenast

School of Chemistry, University of Bristol, Cantock's Close, Bristol, BS8 1TS, United Kingdom.

1 publication 2023 – 2023
MiceTissue DistributionChelating AgentsTechnetiumRadioisotopes

What does Martin A Heckenast research?

Martin A Heckenast studies how to connect special compounds that can bind to radioactive atoms, specifically technetium-99m and rhenium-188, to glucose molecules. These combinations hold promise for new medical applications, as they can improve the effectiveness of imaging techniques used for diagnosing problems like tumors while also delivering targeted treatment, such as radiation therapy, directly to cancer cells. His research aims to create a streamlined approach that enhances the abilities of existing medical tools, making it easier for doctors to both see and treat diseases in a single process.

Key findings

  • Developed a technique with over 95% success rate for attaching radioactive atoms to glucose-based compounds.
  • The resulting molecules travel quickly through the bloodstream and are safely cleared through the kidneys.
  • Demonstrated the stability of these molecules in the body, which is crucial for their effectiveness as medical tracers.

Frequently asked questions

Does Dr. Heckenast study cancer treatment?
Yes, he researches methods to use radioactive materials for both diagnosing and treating cancer.
What technologies has Dr. Heckenast developed?
He has developed a new chemical method for creating medical tracers that combine imaging and therapeutic functions.
Is Dr. Heckenast's work applicable to medical imaging?
Yes, his research focuses on enhancing medical imaging techniques to better detect tumors using new tracers.

Publications in plain English

Diphosphine Bioconjugates via Pt(0)-Catalyzed Hydrophosphination. A Versatile Chelator Platform for Technetium-99m and Rhenium-188 Radiolabeling of Biomolecules.

2023

Inorganic chemistry

Nuttall RE, Pham TT, Chadwick AC, Hungnes IN, Firth G +5 more

Plain English
Researchers developed a new chemical method to attach glucose molecules to special compounds that can grab onto radioactive atoms (technetium and rhenium), making it possible to create medical tracers that both diagnose diseases and treat them simultaneously. They successfully attached these radioactive atoms to glucose-based compounds with very high efficiency (over 95% success rate), and tests in mice showed the resulting molecules traveled quickly through the bloodstream and were safely cleared through the kidneys while remaining stable in the body. This breakthrough could allow doctors to use a single type of molecule for both detecting tumors with imaging scans and destroying cancer cells with radiation therapy.

PubMed

Publication data sourced from PubMed . Plain-English summaries generated by AI. Not medical advice.